MS4A6A

Across TCGA pan-cancer cohorts, MS4A6A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MS4A6A data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher MS4A6A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MS4A6A expression acts as an unfavorable survival marker.

PRAD and SCLC are the cancer types where MS4A6A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.617	0.886	.029	6	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MS4A6A–PRAD (DFS)

Open the PRAD breakdown →